Results 51 to 60 of about 4,942,192 (218)

Paradoxical Alopecia Areata Induced by IL‐17 and IL‐23 Inhibitors: A Systematic Review

open access: yesJEADV Clinical Practice, EarlyView.
This systematic review identifies consistent clinical patterns of alopecia areata associated with IL‐17 and IL‐23 inhibitors, most frequently involving secukinumab and ustekinumab. Disease severity varied widely, and management often required biologic discontinuation or therapeutic switching.
Isabella Kamholtz   +2 more
wiley   +1 more source

Nail Lichen Planus in Children ‐ Epidemiology, Pathogenesis, Clinical Presentation, and Treatment

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Nail lichen planus (NLP) is a chronic inflammatory disorder that, while rare in children compared to adults, represents a significant cause of pediatric nail dystrophy that requires early recognition to prevent permanent scarring and nail loss.
Francesca Pampaloni, Matilde Iorizzo
wiley   +1 more source

Therapy of autoimmune bullous diseases

open access: yesTherapeutics and Clinical Risk Management, 2007
Autoimmune bullous diseases result from an immune response to molecular components of the desmosome or basement membrane. Bullous diseases are associated with a high degree of morbidity and occasional mortality. Therapy of bullous diseases consists of suppressing the immune system, controlling inflammation and improving healing of erosions.
openaire   +3 more sources

Autoimmunity and immunological tolerance in autoimmune bullous diseases

open access: yesInternational Immunology, 2019
Abstract Autoimmune diseases are devastating conditions in which the immune system is directed against the host, leading to life-threatening destruction of organs. Although autoantigens are ill-defined in most autoimmune diseases, this is not the case in the skin.
Hayato Takahashi   +6 more
openaire   +2 more sources

Chinese version of the treatment of autoimmune bullous disease quality of life questionnaire: Reliability and validity

open access: yes, 2018
Background: Treatments for autoimmune blistering disease carry significant risks of medical complications and can affect the patient's quality of life. Recently, the Treatment of Autoimmune Bullous Disease Quality of Life questionnaire was developed in ...
Baoqi Yang   +13 more
core   +1 more source

Plasma Cell Mucositis: A 20‐Year Retrospective Review at a Tertiary Center

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Plasma cell mucositis (PCM) is a rare, chronic inflammatory condition of mucosal surfaces that is likely underdiagnosed and underreported, with limited data on its clinical characteristics, extracavitary involvement, and treatment outcomes.
Miguel A. Aristizabal‐Torres   +4 more
wiley   +1 more source

Dipeptidyl Peptidase‐4 Inhibitor Use and Risk of Pemphigus Vulgaris and Foliaceus: A Retrospective Cohort Study Using Databases of the Korea National Health Insurance Claims and the National Health Screening Examination

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Although population‐based studies have reported an increased risk of bullous pemphigoid and pemphigus associated with dipeptidyl peptidase‐4 (DPP‐4) inhibitors, there is limited, well‐designed epidemiological evidence for pemphigus vulgaris (PV), which has only been supported by case reports thus far.
Jaein Lee, Jae Hyun Bae, Seokyung Hahn
wiley   +1 more source

Epidemiological Study of Autoimmune Bullous Dermatoses in Northeastern Romania

open access: yesDiagnostics, 2023
Background: Autoimmune bullous diseases (ABDs) are a rare but significant group of dermatoses that pose great challenges to the treating dermatologist. ABDs are characterized by the presence of tissue-bound and circulating autoantibodies directed against
Ioana Adriana Popescu   +8 more
doaj   +1 more source

Association between Antibodies to the MR 67,000 Isoform of Glutamate Decarboxylase (GAD) and Type 1 (Insulin-Dependent) Diabetes Mellitus with Coexisting Autoimmune Polyendocrine Syndrome Type II [PDF]

open access: yes, 1994
By using an immunoprecipitation assay, we analysed reactivity of autoantibodies to human recombinant GAD65 and GAD67 in sera from patients with autoimmune polyendocrine syndrome Type II (APS II) with and without Type 1 (insulin-dependent) diabetes ...
Seißler, Jochen   +6 more
core   +1 more source

Home - About - Disclaimer - Privacy